Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

Passero L, Simon TA, Zhong Y, Zhuo J, Varga S, Armstrong AW. Role of real-world evidence from patient registries for psoriasis in decision-making: a systematic[...]

Wang J, Patel S, Kolker S, Bennett RG. Onycholemmal Carcinoma Excised by Mohs Micrographic Surgery With Immediate Frozen Section Bone Examination. Dermatol Surg. 2025 Dec[...]

Yan MJ, Jiang YC, Wongvibulsin S, Chen ST. Assessing public interest in artificial intelligence in dermatology: A Google Trends analysis. JID Innov. 2025 Nov 17;6(2):100435.[...]